SCLX vs. OMGA, MOLN, VIGL, LIFE, BCAB, SGMO, CRDL, BLUE, DBVT, and VXRT
Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Omega Therapeutics (OMGA), Molecular Partners (MOLN), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), BioAtla (BCAB), Sangamo Therapeutics (SGMO), Cardiol Therapeutics (CRDL), bluebird bio (BLUE), DBV Technologies (DBVT), and Vaxart (VXRT). These companies are all part of the "biological products, except diagnostic" industry.
Scilex (NASDAQ:SCLX) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
Omega Therapeutics has lower revenue, but higher earnings than Scilex. Omega Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.
Scilex has a net margin of -229.47% compared to Omega Therapeutics' net margin of -1,868.35%. Scilex's return on equity of 0.00% beat Omega Therapeutics' return on equity.
Omega Therapeutics received 19 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 71.88% of users gave Omega Therapeutics an outperform vote.
Scilex presently has a consensus price target of $6.00, indicating a potential upside of 589.66%. Omega Therapeutics has a consensus price target of $10.00, indicating a potential upside of 320.17%. Given Scilex's higher probable upside, analysts clearly believe Scilex is more favorable than Omega Therapeutics.
69.7% of Scilex shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 8.7% of Scilex shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Omega Therapeutics had 11 more articles in the media than Scilex. MarketBeat recorded 21 mentions for Omega Therapeutics and 10 mentions for Scilex. Omega Therapeutics' average media sentiment score of 0.62 beat Scilex's score of 0.31 indicating that Omega Therapeutics is being referred to more favorably in the news media.
Scilex has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
Summary
Omega Therapeutics beats Scilex on 10 of the 17 factors compared between the two stocks.
Get Scilex News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
